Notizia - Recent Pharma, Healthcare and Biotech Happenings
Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Jun 04, 2019
Table of Contents
Phase III trials of Sanofi’s investigational anti-CD38 monoclonal antibody, isatuximab combination therapy were successful in lowering down the multiple myeloma tumor rate in 60% of the patients in comparison to 35% reduction in the patients taking the standard therapy consisting pomalidomide and dexamethasone only. There exist several treatment options for multiple myeloma but still, it is incurable as the patient eventually go into remission and relapses.
Blueprint Medicines’ RET inhibitor BLU-667 shrank tumor rate in 60% of a difficult-to-treat group of lung cancer patients. Lung cancer patients with RET mutations were not being benefitted from the targeted therapy. The research revealed that BLU-667 is also stopping the progression of tumor in sites other than lungs such as the brain. BLU-667 was also tested on patients with RET-altered medullary thyroid cancer (MTC), which shrank tumors in 63% of patients had previously been treated with Sanofi Genzyme’s Caprelsa or Exelixis’ Cabometyx.
Astellas and Seattle Genetics’ collaborative drug led to a significant decline in tumor in patients with advanced bladder cancer. Enfortumab vedotin an antibody-drug conjugate combines an antibody that targets a specific protein present on the surface of tumor cells. These cells have already been pretreated with chemotherapy and the drug penetrates and kills cancer cells. The most encouraging part of the research was the ability of Enfortumab in shrinking tumors in 38% of patients suffering from bladder cancer, which has already spread to the liver.
Novartis breast cancer drug Kisqali positively extended the lives of younger women who developed breast cancer. The drug known for slowing down the progression of the breast cancer has also been improving the survival rate of the women who have not yet hit the menopause and also sensitive to estrogen and lacking a protein called HER2.
Article in PDF
